Bcl-2-like protein 1 (Bcl-xS isoform) (Bcl-xS)

Bcl-2-like protein 1 (Bcl-xS isoform) is the short, pro-apoptotic splice variant of the BCL2L1 gene, a member of the Bcl-2 protein family[2][5][7]. Alternative splicing of the BCL2L1 pre-mRNA gives rise to two major isoforms: the anti-apoptotic Bcl-xL (long) and the pro-apoptotic Bcl-xS (short). Bcl-xS is defined by the absence of the BH1 and BH2 domains, containing only the BH3, BH4, transmembrane, and loop regions[7]. Its function is to promote apoptosis by antagonizing the anti-apoptotic effects of Bcl-xL and Bcl-2 proteins through heterodimerization, which results in the release of pro-apoptotic effector proteins such as Bak and Bax from inhibition[1][2][7]. Bcl-xS localizes to the mitochondrial outer membrane, where it facilitates mitochondrial outer membrane permeabilization, cytochrome C release, and activation of the apoptotic cascade[7]. Increased Bcl-xS expression has been associated with heightened susceptibility to apoptosis and is experimentally targeted for cancer therapy to overcome resistance mechanisms conferred by high Bcl-xL[1][4]. The Bcl-xL/Bcl-xS balance is a key determinant of cell survival and death, and dysregulation of their splicing is implicated in cancer, neurodegeneration, and other diseases[2][5]. Bcl-xS gene expression refers to the level of the Bcl-xS isoform, rather than a specific receptor, enzyme, or small-molecule target. Therapeutically, its expression is considered a targetable node in the regulation of cell fate, especially in oncology[3][4].

Other names

BCL2-like 1 short isoformBcl-x short isoformBCL2L1 (gene encoding both Bcl-xL and Bcl-xS)bcl-xS

Promotion of apoptosis by antagonizing anti-apoptotic Bcl-xL and Bcl-2 family proteins; Disruption of mitochondrial membrane integrity